

Contents lists available at ScienceDirect

Pharmacological Research



journal homepage: www.elsevier.com/locate/yphrs

Photopharmacological manipulation of amygdala metabotropic glutamate receptor mGlu4 alleviates neuropathic pain



Vanessa Pereira^a, Juri Aparicio Arias^a, Amadeu Llebaria^b, Cyril Goudet^{a,*,1}

^a IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France

^b MCS, Laboratory of Medicinal Chemistry & Synthesis, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain

ARTICLE INFO

Keywords: Pain Amygdala GPCR Photopharmacology Metabotropic glutamate receptors

ABSTRACT

Neuropathic pain is a common health problem resulting in exacerbated response to noxious and non noxious stimuli, as well as impaired emotional and cognitive responses. Unfortunately, neuropathic pain is also one of the most difficult pain syndromes to manage, highlighting the importance of better understanding the brain regions and neuromodulatory mechanisms involved in its regulation. Among the many interconnected brain areas which process pain, the amygdala is known to play an important role in the integration of sensory and emotional pain signals. Here we questioned the ability of a recently identified neuromodulatory mechanism associated with the metabotropic glutamate receptors mGlu₄ in the amygdala to modulate neuropathic pain. In a murine model of peripheral mononeuropathy, we demonstrate that pharmacological activation of amygdala mGlu4 efficiently alleviates sensory and depressive-like symptoms in both male and female mice. Moreover, we reveal a differential modulation of these symptoms. Activating mGlu4 in the contralateral amygdala relative to the side of the mononeuropathy, is necessary and sufficient to relieve both sensory and depressive-like symptoms, while ipsilateral activation solely reduces depressive-like symptoms. Furthermore, using photopharmacology, a recent strategy allowing precise photocontrol of endogenous proteins, we further demonstrate the dynamic alleviation of neuropathic pain through light-dependent facilitation of mGlu4 by a photoswitchable positive allosteric modulator. Finally, coupling photopharmacology and analgesic conditioned place preference, we show a significant pain-reducing effect of mGlu4 activation. Taken together, these data highlight the analgesic potential of enhancing amygdala mGlu4 activity to counteract neuropathy reinforcing its therapeutic interest for the treatment of pathological pain.

1. Introduction

Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. It is a common and complex health problem, which greatly impairs the quality of life of 7–10% of the population worlwide [9,38]. Unfortunately, neuropathic pain is one of the most difficult pain syndromes to manage [2]. Indeed, the most commonly prescribed treatments for neuropathic pain (anticonvulsants, antidepressants) have moderate efficacy at best and are associated with side effects that limit their use. This underlines the importance of understanding the brain circuits and neuromodulatory mechanisms of pain in order to improve treatment options.

The processing of pain-related information behind the sensory,

cognitive and emotional–affective aspects of pain is very complex and involves many interconnected brain areas [22]. Among them, the amygdala is known to be a critical region that integrates sensory and pain signals [27]. The amygdala receives pain-related information mainly from the thalamus, cortical areas and the parabrachial nucleus [26,27,30]. The amygdala is composed of multiple interconnected nuclei, comprising the basolateral (BLA) and central (CeA) nuclei and the intercalated cells (ITC), which have all been linked to pain-related functions. Within amygdala, various neuromodulatory systems are implicated in the modulation of those functions, such as opioids [28], cannabinoids [16,35], neuropeptides [28,40], as well as glutamate [20, 29,31].

Glutamate is one of the main neurotransmitters involved in the

¹ ORCID: 0000–0002-8255–3535

https://doi.org/10.1016/j.phrs.2022.106602

Received 15 November 2022; Received in revised form 2 December 2022; Accepted 6 December 2022 Available online 15 December 2022 1043-6618/© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

^{*} Correspondence to: Institut de Genomique Fonctionnelle, Univ Montpellier, Inserm, CNRS, 141 rue de la Cardonille, 34094 Montpellier cedex 5, Fance. *E-mail address*: cyril.goudet@igf.cnrs.fr (C. Goudet).

transmission of pain-related information throughout the nervous system. It exerts its action via the activation of ionotropic and metabotropic receptors. Metabotropic glutamate receptors (mGlu) are G proteincoupled receptors activated by the neurotransmitter glutamate [14] and several studies have highlighted the analgesic potential of these receptors [24,31]. Recently, a subtype of the mGlu receptor family, mGlu₄, has been identified in the amygdala where it acts as a neuromodulator of sensory and anxiodepressive symptoms associated with persistent inflammatory pain [45]. These receptors are present mainly in presynaptic elements of both glutamatergic and GABAergic neurons within the lateral (LA) and basolateral amygdala (BLA), and they downregulate the transmission coming from the thalamus [45]. mGlu₄ receptors could make interesting analgesic targets against pathological pain because, while leaving acute pain in naïve animals unchanged, systemic or local administration of mGlu₄ agonists in the spinal cord or the amygdala alleviates pain in animal models of chronic pain [12,39, 41,45,8]. However, the role of these receptors in chronic pain from various etiologies remains to be determined.

In the present study, we questioned the ability of amygdala mGlu₄ receptors to modulate neuropathic pain. To that aim, we combined classical behavioral pharmacology in a mouse preclinical model of peripheral mononeuropathy and photopharmacology, a recent strategy allowing a precise spatiotemporal control of deep brain endogenous targets by light-operated ligands [3,18].

2. Materials and methods

2.1. Animals

Experiments were performed on 8- to 12-week-old C57BL/6J male and female mice (Charles River). Animals were treated in accordance with the European Community Council Directive 2010/63/EU. Experimental protocols were approved by the regional animal welfare committee (CEEA-LR) with the guidelines of the French Agriculture and Forestry Ministry (D34–172–13). All efforts were made to minimize animal suffering and to reduce their number according to the 3R principles.

2.2. Stereotaxic implantation of cannulas

Prior to neuropathy induction and behavioral testing, guide cannulas for pharmacology (PlasticsOne, Roanoke, VA) or hybrid opto/fluidic cannulas for photopharmacology (DORIC lenses, Quebec, Canada) were implanted unilaterally by stereotaxic surgery on anesthetized mice. Cannulas were placed over the intermediate capsule of right or left amygdala (-1.34 mm anteroposterior (AP); ± 2.9 mm mediolateral (ML); and -4.25 mm dorsoventral (DV)). After 1 week of recovery from the stereotaxic surgery, animals were first subjected to different behavioral tests to measure their basal locomotor activity, mechanical or thermal sensitivity and grooming behavior in order to establish a baseline. At the end of the series of behavioral experiments, brains were post-fixed to check the cannula locations.

2.3. Peripheral mononeuropathy induction

Induction was performed after 1 week of recovery from stereotaxic implantation and baseline measurements. We used the "Cuff model" of neuropathic pain, known to induce long-lasting sensory and anxiodepressive symptoms in mice [42]. Peripheral mononeuropathy was induced by the unilateral implantation of a cuff made of a short polyethylene tube (2 mm) around the main branch of the sciatic nerve of the right or left hind paw of anesthetized mice [43]. Sham surgeries followed the same procedure, but without implantation.

2.4. Behavioral experiments

Mechanical sensitivity was evaluated using the von Frey method. The mechanical force required to elicit a paw withdrawal response in 50% of animals (in grams) was determined using the simplified "updown" Von Frey method [4]. Heat sensitity was measured using the Hargreaves test. A radiant infrared heat stimulus was focused on the plantar surface of the hindpaws of mice to determine the time taken (in seconds) to withdraw from the heat stimulus [15]. Depressive-like behavior was assessed using the splash test [21]. The duration that mice spent pursuing grooming behavior after spraying a 10% sucrose solution on their dorsal coat was recorded manually over a total period of 5 min for classical pharmacology and 9 min for photopharmacology experiments.

These behaviors were tested on healthy mice (baseline, before surgery) and on neuropathic or sham operated mice (>14 days after the surgery, as indicated in the corresponding figures) after intra-amygdala injection of drugs or their vehicle. Locomotor activity and additional behaviors were also recorded (Supplemental Fig. 1).

2.5. In vivo photopharmacology

In vivo photopharmacology was applied in experiments measuring mechanical and heat allodynia, depressive-like behavior and in analgesic conditioned place preference experiments in mononeuropathic mice. Experiments were performed on mice stereotaxically implanted with hybrid opto/fluidic cannulas. Mice were connected via a catheter to a minipump and via an optical fiber to a LED source, allowing the local delivery of drugs and light in the amygdala in freely moving animals. We used a LED light source (DORIC lenses, Quebec, Canada) combining two wavelengths (UV: 385 nm; Green: 505 nm) which are independently controlled via the LED driver software (Doric Lenses, Quebec, Canada) and connected through a rotary joint to an optical fiber (fiber diameter: 200 μ m, NA = 0.53). Mice were habituated to be connected daily during one week before the tests. Tests were performed after intra-amygdala injection of optogluram or vehicle. Mice received 50 ms light pulses at 10 Hz frequency and a light power of 8.0 mW for 385 nm wavelength and 2.0 mW for 505 nm wavelength. The duration of light exposure was adapted for each behavioral test. Typically, light application started 15 min following injection, when the ligand reaches its maximal effect (as determined in absence of light).

2.6. Analgesic conditioned place preference (aCPP)

In order to evaluate the analgesic potential of mGlu₄ photocontrol in absence of external stimuli, we used the aCPP paradigm [37], combined with photopharmacology. The aCPP apparatus consists in a two-chamber arena presenting different contexts (striped or dotted wall patterns), which are connected through a central open door. One chamber was defined as the "violet chamber" and the other one as the "green chamber". The illumination is automatically controlled through a video tracking device coupled to the light source controller (EthoVision, Noldus, Wageningen, Netherlands). When the mouse is detected in the "violet chamber", it receives a 385 nm LED illumination in the amygdala through an optic fiber. On the other hand, when the mouse is in the "green chamber", it receives a 505 nm LED illumination in the amygdala. Following a first session of habituation to the arena in absence of treatment, mice were submitted to 10 conditioning episodes of 5 min, twice daily for 5 days. During each conditioning episode, neuropathic or sham operated mice were injected with either vehicle (PBS) or optogluram (30 μ M, 500nL in PBS). Fifteen minutes after injection (when drug reached its maximal effect), mice were placed for 5 min in the arena and allowed to move freely. Mice were first placed alternatively in one or the other chamber. The 6th day, the animals were placed in the center of the arena, receiving no drug or light treatment, and their real-time place preference was measured during 5 min through a video


tracking software.

2.7. Ligands and chemicals

All chemicals were reagent grade (Merck, or Sigma, Germany). Optogluram and LSP4–2022 were synthesized following the experimental procedures previously reported [13,32]. The doses of LSP4–2022 and optogluram were selected based on doses previously used in the literature [45].

2.8. Statistics

All data are reported as mean \pm standard error of the mean (SEM).



Number of mice and statistical tests that were performed on datasets are indicated in Figure Legends. Data were analyzed using Prism software (GraphPad, La Jolla, CA, USA) using one-way or two-way analysis of variance (ANOVA) and the appropriate post-hoc tests for multiple comparisons to determine the p-value. Data were considered significant when p < 0.05. A summary of statistical analysis of data in figure panels is presented in supplemental table 1.

Fig. 1. Cuff-induced mononeuropathic pain model leads to sensory and depressive-like symptoms in male and female mice symptoms. Peripheral mononeuropathy was induced by positioning a cuff around the sciatic nerve of the left or right hind paw of male and female mice. a: Experimental design and timeline of behavioral tests. b, e: Mechanical allodynia was observed both in male or female mice, 14 days after implantation of the Cuff either on the left or right hind paw, as indicated by the significant reduction of the ipsilateral paw withdrawal thresholds measured using the Von Frey technique. c, f: Heat allodynia was observed both in male or female mice, 14 days after implantation of the Cuff either on the left or right hind paw, as indicated by the significant reduction of the latency to withdraw the paw in the Hargreaves test. d, g: Depressive-like behavior assessed in the splash test revealed a significant decrease in grooming duration in both male and female Cuff mice, 15 days after induction. Data are expressed as mean \pm SEM of n = 7-10 (male) or n = 7-10 (female) per group. Difference between D₀ vs D₁₄ (or D₀ vs D₁₅) was analyzed by a two-way ANOVA folby Sidak's post-hoc lowed test. * ** *p < 0.0001; * **p < 0.001; * *p < 0.01; * *p < 0.01; *p < 0.05.

3. Results

3.1. Peripheral mononeuropathy induces mechanical and heat allodynia and depressive-like symptoms in male and female mice

Throughout this study, we used a preclinical model of peripheral mononeuropathy named the "cuff model" which is provoked by the unilateral implantation of a tube enclosing the sciatic nerve. In mice, this model is known to induce long-lasting sensory symptoms such as mechanical and heat allodynia, as well as anxiodepressive-like symptoms such as a defect in grooming behavior [42]. This model reproduces similar symptoms to those of patients with neuropathic pain who often suffer from allodynia, a pathological state in which an innocuous stimuli becomes painful [2], as well as depression which is one of the most common comorbidities of neuropathic pain [9].

We measured mechanical and thermal sensitivity as well as grooming behavior before surgery (Baseline, D0), and two weeks after the induction (Fig. 1a). After 14 days, we observed a significant decrease in the paw withdrawal threshold on the side of the lesion, as measured by the Von Frey technique (Fig. 1b, e). We also observed a significant decrease of the latency to withdraw the paw from heat source, as measured by the Hargreaves test (Fig. 1c, f). This indicates that the chronic constriction of the sciatic nerve provoked by the cuff induces both mechanical and heat allodynia. In addition, 15 days after induction, mice elicit a significantly reduced duration of grooming behavior when submitted to the splash test, indicative of depressive-like behavior (Fig. 1c).

3.2. Activation of mGlu₄ in the amygdala relieves neuropathic pain symptoms in male mice

We then questioned the ability of amygdala mGlu₄ to modulate symptoms of neuropathic pain. To this end, we first used a selective mGlu₄ agonist, LSP4–2022 [13], that we injected unilaterally (5 μ M, 500 nL in PBS) either in the ipsilateral or contralateral amygdala as compared to the peripheral mononeuropathy on the right or left hind paw.

We first assessed the potential modulation of neuropathic pain symptoms by right or left amygdala mGlu₄ when the peripheral mononeuropathy is on the left hind paw. Interestingly, we observed that activation of the right amygdala mGlu₄ significantly reduces mechanical or heat allodynia whereas activation of left amygdala mGlu₄ does not modify them (Figs. 2a and 2b). On the other hand, activation of mGlu₄ in both right or left amygdala significantly restores grooming behaviour in those mice (Fig. 2c).

To verify whether this asymmetrical modulation of allodynia could result from a specialization of the right amygdala in the modulation of certain pain-related functions as previously observed [1], we performed a series of mirror experiments in which the peripheral mononeuropathy was on the right hind paw. When the neuropathy is on the right side, activation of the left amygdala mGlu₄ significantly reduces mechanical or heat allodynia whereas activation of right amygdala mGlu₄ does not modify them (Figs. 2d and 2e). Activation of mGlu₄ in both right or left amygdala significantly restores grooming behaviour in those mice (Fig. 2f).

This indicates that activation of $mGlu_4$ in the amygdala contralateral to the lesion is necessary and sufficient to relieve both sensory and depressive symptoms of peripheral mononeuropathy in male mice, while activation of $mGlu_4$ in the ipsilateral amygdala solely abolishes depressive-like behavior.

Another interesting observation is that activation of amygdala mGlu₄ by local injection of LSP4–2022 does not significantly modify mechanical or heat sensitivity, as well as grooming behavior, in Sham operated mice (supplemental Fig. 2). As previously reported [12,39,41,45], it seems that mGlu₄ activation solely reduces hypersensitivity or abnormal behaviors associated with pathological states without significantly affecting normal sensitivity or behavior in healthy mice.

3.3. Activation of mGlu₄ in the amygdala also relieves neuropathic pain symptoms in female mice

Chronic pain exhibits a higher prevalence in women than in men [9]. Over the past years, preclinical studies have highlighted several sexual dismorphisms in pain mechanisms [33,36,5] notably in the amygdala [34]. Thus, we sought to determine whether amygdala mGlu₄ activation can also modulate neuropathic pain symptoms in female mice. To this end, we assessed the potential modulation of neuropathic pain symptoms following activation of mGlu₄ by the agonist LSP4–2022 in the right or left amygdala in female mice suffering from peripheral mononeuropathy in their left hind paw.

First, as observed in male mice, the chronic constriction of the sciatic nerve provokes mechanical and thermal allodynia, as well as depressivelike symptoms in female mice. Then, following local injection of LSP4–2022, we obtained similar results as in males: i) contralateral activation is required to significantly diminish mechanical or heat allodynia while ipsilateral activation does not modify these sensory symptoms (Fig. 2g and 2h) and ii) either ipsi- or contralateral activation significantly restore grooming behaviour in female mice (Fig. 2i).

This series of experiments demonstrates that activation of amygdala mGlu₄ relieves neuropathic pain symptoms in both male and female mice.


3.4. Photocontrolled-activation of amygdala mGlu₄ dynamically alleviates neuropathic pain symptoms

We then used photopharmacology, an emerging strategy to control the biological activity of endogenous proteins by light, to assess whether amygdala mGlu₄ can exert a dynamic modulation of neuropathic painrelated symptoms. This technique allows a precise spatiotemporal control of deep brain endogenous targets by light-operated ligands [3,18].

We used optogluram, a photoswitchable positive allosteric modulator (PAM) of mGlu₄ receptors, to photocontrol amygdala mGlu₄ receptors [32,45]. Optogluram posseses an azobenzene moiety in its scaffold which acts as a chemical switch. Optogluram is active in the dark and under illumination with violet light, isomerizes from its active trans-isomer to its inactive cis-isomer. Under subsequent illumination with green light, it switches back to its trans active isomer [45]. Experiments were performed on mice implanted with hybrid optic-fluidic cannula connected to a minipump for drug injection, and to a LED source through optic fibers for illumination. After a basal measurement at t_0 , ligand or vehicle were injected unilaterally either in the ipsilateral or contralateral amygdala as compared to the peripheral mononeuropathy on the left hind paw. After 15 min, the mechanical and heat sensitivity is measured to determine the effect of the treatment on these parameters. Then, from 15 to 45 min, we applied 3 successive cycles of violet/green illumination to deactivate/reactivate optogluram and measured mechanical or heat sensitivity after each illumination period of 5 min. We verified that light by itself does not modify the different symptoms measured in animals injected with saline solution (500 nL of PBS). Violet- or green-light illumination in the amygdala had no effect on the measured parameters in absence of the photoswitchable mGlu₄ PAM (Fig. 3a-c).

In the dark, neuropathic-induced mechanical or heat allodynia are abolished 15 min after contralateral intra-amygdala microinjection of optogluram (30 μ M in 500nL of PBS), but not following ipsilateral injection. As can be seen in Figs. 3d and 3e, the anti-allodynic action of optogluram is switched off following a 5 min illumination with violet light (λ = 385 nm, 8.0 mW, 10 Hz) and recovered after 5 min of green illumination (λ = 505 nm, 2.0 mW, 10 Hz). Intra-amygdala injection of optogluram also reduced the depressive-like behavior of neuropathic mice measured with the splash test. In the dark, 15 min after ipsi- or contralateral administration, optogluram (30 μ M in 500nL of PBS)

Pharmacological Research 187 (2023) 106602



(caption on next page)

Fig. 2. mGlu₄ activation in the amygdala differentially inhibits hypersensitivity and depressive-like behaviour in male and female neuropathic mice. Peripheral mononeuropathy was induced by positioning a cuff around the sciatic nerve of the left or right hind paw of male or female mice. Beforehand, mice were implanted with a cannula on the ipsilateral or contralateral amygdala (left cuff for females). On the test day, at to, mice were injected with the selective mGlu₄ agonist, LSP4-2022 (5 µM, 500 nL in PBS) either on the ipsi or contralateral amygdala to the mononeuropathy and the subsequent effects on neuropathic pain symptoms were measured. a, d: Effect on mechanical allodynia of mGlu₄ activation on the ipsilateral or contralateral amygdala on male mice with a mononeuropathy on the left or right hind paw. Mechanical allodynia as determined by the Von Frey technique. b, e: Effect on heat allodynia of mGlu₄ activation on the ipsilateral or contralateral amygdala on male mice with a mononeuropathy on the right or left hind paw. Thermal allodynia as determined by Hargreaves method. c, f: Effect on depressive-like symptoms of mGlu₄ activation on the ipsilateral or contralateral amygdala on male mice with a mononeuropathy on the right or left hind paw. Depressive-like symptoms as determined by the Splash Test. g: Effect on mechanical allodynia of mGlu4 activation on the ipsilateral or contralateral amygdala on female mice with a mononeuropathy on the left hind paw. Mechanical allodynia as determined by the Von Frey technique. Mean threshold \pm SEM (g), t_x vs t₀ (0 min), two-way ANOVA, Dunnett's post-hoc test. h: Effect on heat allodynia of mGlu4 activation on the ipsilateral or contralateral amygdala on female mice with a mononeuropathy on the left hind paw. Thermal allodynia as determined by Hargreaves method. i: Effect on depressive-like symptoms of mGlu4 activation on the ipsilateral or contralateral amygdala on female mice with a mononeuropathy on the left hind paw. Depressive-like symptoms as determined by the Splash Test by measuring the time spent grooming. Data are expressed as mean \pm SEM of n = 7-10 (male) or n = 7-10 (female) per group. Difference between t_x vs t₀ (0 min) was analyzed by a two-way ANOVA followed by Dunnet's post-hoc test for panels a, b, d, e and Tukey's post-hoc test for panels c, f, i. * *** * p < 0.0001; * ** p < 0.001; *p < 0.01; *p < 0.05.

increased the grooming duration of cuff-mice, whereas 3 min of violet light illumination reduced it to the levels observed in vehicle-treated cuff mice. Then, the increase of the grooming duration is restored following 3 min of green light illumination (Fig. 3f). Also, photopharmacological manipulation of amygdala mGlu₄ using optogluram does not modify mechanical sensitivity, thermal sensitivity or grooming in Sham operated mice (supplemental Fig. 3), similar to what was observed following mGlu₄ activation with the agonist LSP4–2022 (supplemental Fig. 2).

Taken together, these results demonstrate the dynamic nature of mGlu₄ control over neuropathic pain-related symptoms.

3.5. Amygdala $mGlu_4$ photocontrolled activation promotes analgesic conditioned place preference

Next, we used the analgesic conditioned place preference paradigm (aCPP)[37] to evaluate the analgesic potential of amygdala mGlu₄ activation in neuropathic mice, without the involvement of external noxious stimuli. For enhanced precision, we coupled aCPP with photopharmacology.

Experiments were performed in right implanted male mice, while the mononeuropathy was on the left hind paw. Experimental conditions for photopharmacological manipulations were similar to those described above, except that illumination was automatically controlled through a videotracking device which detects the location of the mouse.

Conditioning was performed twice daily for 5 days. During this conditioning period, neuropathic or sham mice received an intraamygdala administration of either vehicle (500 nL of PBS) or optogluram (30 μ M in 500nL of PBS) and, depending on their position in a two-chamber arena, they automatically received either a green or violet illumination through an optic fiber (Fig. 4a, b). We verified that chronic treatment with optogluram does not lead to tolerance. Neuropathic mice received an intra-amygdala microinjection of optogluram (30 μ M in 500nL PBS) twice daily for 5 days, which corresponds to the conditioning period. We measured the anti-allodynic effect of optogluram on day 6 (supplementary figure 4) and observed no difference on the peak effect of the drug (15 min following intra-amygdala injection of optogluram) on the paw withdrawal threshold measured by the Von Frey technique that was measured at D14 post-induction.


On the 6th day, we tested the eventual preference of neuropathic or sham mice for the "green chamber" (in which optogluram was switchedon through green illumination) over the "violet chamber" (in which it was switched-off through violet illumination). During this test, mice received no drug or light treatment. The time spent in each chamber was measured using the videotracking device. As can be seen in Fig. 4c-f, the group of conditioned neuropathic mice that received the optogluram treatment significantly preferred the green area, contrary to the conditioned mice that received saline which exhibited no preference. No difference between the time spent in the violet or green areas was observed in non-conditioned Sham or neuropathic mice (supplemental Fig. 5 and 6).

These experiments demonstrate the analgesic potential of amygdala mGlu₄ activation in neuropathic mice.

4. Discussion

In this study we demonstrate that sensory and depressive symptoms of neuropathic pain are rapidly and efficiently relieved under mGlu₄ control in male and female mice, and that ipsi- or contralateral amygdala differentially contribute to the modulation of these symptoms. The contralateral amygdala is necessary and sufficient to alleviate both sensory and depressive-like symptoms resulting from peripheral mononeuropathy, while mGlu₄ activation in the ipsilateral amygdala only reduces depressive-like symptoms (Fig. 5). Using photopharmacology, we reveal that amygdala mGlu₄ exerts a rapid and dynamic control over neuropathic pain-related symptoms. The analgesic potential of amygdala mGlu₄ activation was further underlined in the conditioned place preference paradigm. This method has been successfully used to probe the efficacy of various analgesics [25,37]. The interest of aCPP is that subject animals determine by themselves the analgesic efficacy of a given treatment, without the involvement of external noxious stimuli. To our knowledge, this is the first time that aCPP has been coupled with photopharmacology. All mice received a similar treatment by a photoswitchable mGlu₄ PAM and, depending on their position in a two-chamber arena automatically detected by a videotracking device coupled to the illumination source, the ligand was activated or deactivated by light. After the conditioning period, mice clearly preferred the context in which the activity of amygdala mGlu₄ receptors was potentiated. Also of interest, we did not observe a decrease in the efficacy of anti-allodynic action following repeated treatment by optogluram, indicating a lack of tolerance (supplemental Fig. 4).

Our results extend previous works demonstrating that exogenous activation of mGlu₄ receptors is benificial for chronic pain symptoms. Systemic administration of the mGlu₄ selective agonist LSP4-2022 relieves symptoms of chronic pain from different etiologies [39]. At the spinal cord level, mGlu₄ receptors are found in the inner laminae II of the dorsal horn, a region that receives the afferences from nociceptive Aδand C-fibers, where its activation reduces excitatory neurotransmission through the inhibition of Ca^{2+} entry via N or P/Q type voltage-gated calcium channels in the presynaptic terminal [39]. Intrathecal injection of mGlu₄ agonists, such as LSP4-2022, or PAMs, such as PHCCC or VU0155041, alleviates allodynia and hyperalgesia induced by both inflammatory or neuropathic pain without altering acute pain perception in naive animals [12,39,41]. At the supraspinal level, mGlu₄ receptors have been identified in important regions for pain processing, such as the thalamus [11] and the amygdala [45]. Bilateral activation of amygdala mGlu₄ alleviates pain symptoms in a mouse model of persistent inflammatory pain [45]. Taken together, these results demonstrate



Pharmacological Research 187 (2023) 106602

Fig. 3. Photopharmacological mani pulation of mGlu₄ in the amygdala rapidly and reversibly inhibits hypersensitivity and depressive-like behaviour of neuropathic mice. Effects on neuropathic pain symptoms of amygdala mGlu₄ photocontrolled facilitation by the photoswitchable mGlu4 PAM optogluram were measured on male mice with a cuff implanted around the left hind paw, from 14 to 21 days post induction. Local drug and light delivery was performed through a stereotaxically implanted hybrid optofluidic cannula. On the test day, at t₀, mice were injected unilaterally either with vehicle (500 nL PBS) or optogluram (30 µM, 500 nL in PBS) either on the ipsi or contralateral amygdala to the mononeuropathy. Violet (385 nm, 10 Hz, 8 mW) or green light (505 nm, 10 Hz, 2 mW) was applied by the mean of an optic fiber connected to a LED light source and a controller. a. Lack of effect of light on mechanical allodynia on vehicle-treated mice as determined by the Von Frey technique. b. Lack of effect of light on heat allodynia on vehicletreated mice as determined by Hargreaves method. c. Lack of effect of light on depressive-like symptoms on vehicletreated mice as determined by the Splash Test method. d. Effect of mGlu₄ photocontrolled facilitation on mechanical allodynia as determined by the Von Frey technique. e. Effect of mGlu₄ photocontrolled facilitation on heat allodynia as determined by Hargreaves method. f. Effect of mGlu₄ photocontrolled facilitation on depressive-like symptoms as determined by the Splash Test method. Data are expressed as mean \pm SEM of n = 5 per group. Difference between t_x vs t_0 (0 min) was analyzed by a two-way ANOVA followed by Dunnet's post-hoc test for panels a, b and Tukey's post-hoc test for panels c. * ** *p < 0.0001; * ** p < 0.001; * * p < 0.01; * p < 0.05; ns non significant.

50

50

Time in zone (%)




Fig. 4. Photopharmacological facilitation of amygdala mGlu₄ promotes analgesic conditioned place preference (aCPP) of neuropathic mice. a: Experimental design and timeline of behavioral tests. On these experiments, neuropathy was induced by application of a cuff on the left hind paw of male mice, beforehand implanted with a hybrid optofluidic cannula on the contralateral (right) amygdala. The conditioning took place between from day 21 to day 25, the test day was day 26 post surgery. Mice were submitted to 10 conditioning episodes of 5 min, twice daily for 5 days. During each conditioning episode, animals were injected with either vehicle (PBS) or optogluram (30 µM, 500nL in PBS). Fifteen minutes after injection (when drug reached its maximal effect), mice were placed for 5 min in a two-chambers arena and allowed to move freely. Mice were first placed alternatively in the one or the other chamber. The 6th day, the animals were placed in the center of the arena, receiving no drug or light treatment, and their real-time place preference was measured during 5 min through a videotracking software. b: Schematic representation of the aCPP setup. The arena consists in twochambers with different context (striped or dotted walls) connected through a central open door. The illumination is automatically controlled through a video tracking device coupled to the light source controller. When the mouse is detected in the "violet chamber", it receives a 385 nm LED illumination, while it receives a 505 nm LED illumination when it is in the green chamber. c, d: Test results: representative 5-minutes tracks of a neuropathic mouse which received either vehicle (c) or optogluram (d) during the conditioning period. e, f: Test results: Data are expressed as mean percentage \pm SEM of time spent in the "green chamber" or the "violet chamber" of neuropathic mice treated with Vehicle (n = 8) or with Optogluram (n = 12) during conditioning. Difference between time in Violet vs time in Green area was analyzed by a one-way ANOVA followed by a Tukey's post-hoc test. * *p < 0.01.




Fig. 5. Contralateral amygdala mGlu₄ is necessary and sufficient to relieve both sensory and depressive-like symptoms of peripheral mononeuropathy. Left hindpaw neuropathic pain sensory and depressive symptoms are relieved by right amygdala mGlu₄ activation whereas left amygdala mGlu₄ activation solely abolishes depressivelike symptoms. Conversely, all symptoms resulting from right hindpaw neuropathic pain are relieved by left amygdala mGlu₄ activation whereas right amygdala mGlu₄ activation solely abolishes depressive-like symptoms. Ipso facto, activation of mGlu₄ in either ipsilateral or contralateral amygdala to the mononeuropathy abolishes mice depressive-like behavior.

the ability of $mGlu_4$ to modulate various symptoms of chronic pain of different etiologies without modifying acute pain perception, reinforcing its therapeutic interest for the treatment of pathological pain.

Curiously, we did not observe an asymmetrical lateralization between the right or left amygdala. Indeed, previous studies have described a hemispheric specialization of pain-related functions in amygdala (see [1] for review). For example, independently of the inflamed side, the modulation of mechanic allodynia solely occurs following the blockade of right but not left CeA mGlu5 receptors and ERK pathways [20,6,7]. Similarly, sensitization is only observed in the right CeA following right or left monoarthritis [19]. In our experiments, however, mGlu₄ receptors from both sides can modulate sensory or depressive-like symptoms depending on their relative position to the peripheral mononeuropathy. The key for the modulation of sensory symptoms appears to be the localization on the contralateral side to the constriction of the sciatic nerve. Of note, studies revealing the specialization of amygdala function in pain were performed in CeA [1], whereas the amygdalar expression of mGlu₄ receptors is mainly restricted to terminals arriving in the BLA and the LA, with little or no expression in the CeA [45]. Thus, the absence of specialization of left or right amygdala mGlu4 function could result from the localization of mGlu₄ receptors in the LA and BLA rather than in the CeA.

Interestingly, the fact that amygdala mGlu₄ on the ipsi- or contralateral side to the nerve constriction differentially contributes to pain modulation suggests that mGlu₄ achieves its analgesic effects through the neuromodulation of different circuits (Fig. 5). Indeed, while mGlu₄ activation in the contralateral amygdala to the mononeuropathy relieves both sensory and depressive-like symptoms, their activation on the ipsilateral amygdala solely decreases depressive-like symptoms. This indicates that at least two different circuits are at play, differentially regulating sensory and anxiodepressive components, and that mGlu₄ can modulate both of them. These circuits remain to be identified.

The necessity to activate mGlu₄ on the contralateral side to the mononeuropathy to alleviate hypersensitivity suggests that the regulation of sensory symptoms may occur through a modulation of the sensory modalities coming from thalamus nuclei [27]. Indeed, in the spinothalamic tract, most secondary projection neurons of the spinal cord which transmit nociceptive information received from peripheral sensory neurons decussate and send ascending information terminating in various thalamic nuclei [22]. As a result, activation of the thalamus is significantly greater in the hemisphere contralateral to the stimulus, consistent with its involvement in the processing the sensory-discriminative aspects of pain [44]. This means that peripheral nociceptive information from the left side of the body is transmitted to the right side at the supraspinal level, and conversely. We have previously shown that mGlu₄ receptors are expressed in presynaptic terminals of glutamatergic and GABAergic neurons arriving in the LA and BLA,

where they downregulate the transmission coming from the thalamus [45]. Their activation could in turn normalize the activities of LA and BLA neurons. One of the main targets of those neurons is the CeA. Thus, we can speculate that mGlu₄ may modulate the activity within the BLA-CeA circuit, which has been implicated in the generation and modulation of pain-like behaviors [23,27]. Besides the CeA, several pathways regulating specific aspects of pain originating from BLA have been identified recently. For example, the BLA-mPFC-PAG pathway is crucial for the development of mechanical and thermal hypersensitivity after peripheral nerve injury [17] and could be another pathway involved in the reduction of mechanical and thermal hypersensitivity following mGlu₄ activation. We can also hypothesize that mGlu₄ activation could modulate the neural ensemble within BLA identified by Corder and colleagues that mediates chronic pain unpleasantness [10]. However, these points remain largely speculative and further studies will be required in order to identify the input and output circuits modulated by amygdala mGlu₄ receptors.

In conclusion, this study provides strong evidence for a rapid and reversible reduction of neuropathic pain following activation of mGlu₄ receptors in the amygdala. Together with previous research, it demonstrates that exogenous activation or facilitation of mGlu₄ receptors is beneficial in different preclinical models of chronic pain, underlining their therapeutic potential for the management of chronic pain from various etiologies.

Funding

This work was supported by the International Emerging Action (IEA) from the Centre National de la Recherche Scientifique (CNRS) to CG and AL and by grants from the French National Research Agency (ANR): ANR-16-CE16–0010 to CG and ANR-17-NEU3–0001 under the frame of Neuron Cofund to CG and AL.

Competing Interests

The authors declare no competing interests.

Data availability

No data was used for the research described in the article.

Acknowledgments

The authors wish to thank Dr. Francine Acher for kindly providing LSP4–2022, Dr. Guillaume Lebon, Dr. Julie Le Merrer, Dr. Jérôme Becker and Dr. Laurent Givalois for helpful discussions and Dr. Ebba L. Lagerquist for critical reading of the manuscript. Behavioral experiments

were performed at the *iExplore* facility of Montpellier Biocampus and the authors thank the staff of the facility for their technical help. The illustrative graphics were created with BioRender.com.

CRediT authorship contribution statement

Vanessa Pereira: Conceptualization, Methodology, Investigation, Formal analysis, Writing – review & editing. Juri Aparicio Arias: Investigation, Methodology, Validation, Formal analysis, Writing – review & editing. Amadeu Llebaria: Conceptualization, Resources, Funding acquisition, Writing – review & editing. Cyril Goudet: Conceptualization, Visualization, Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.phrs.2022.106602.

References

- H.N. Allen, H.J. Bobnar, B.J. Kolber, Left and right hemispheric lateralization of the amygdala in pain, Prog. Neurobiol. 196 (2021), 101891.
- [2] S.R.A. Alles, P.A. Smith, Etiology and pharmacology of neuropathic pain, Pharmacol. Rev. 70 (2018) 315–347.
- [3] A.E. Berizzi, C. Goudet, Strategies and considerations of G-protein-coupled receptor photopharmacology, Adv. Pharmacol. 88 (2020) 143–172.
- [4] R.P. Bonin, C. Bories, Y. De Koninck, A simplified up-down method (SUDO) for measuring mechanical nociception in rodents using von Frey filaments, Mol. Pain. 10 (2014) 26.
- [5] D. Cabanero, E. Villalba-Riquelme, G. Fernandez-Ballester, A. Fernandez-Carvajal, A. Ferrer-Montiel, ThermoTRP channels in pain sexual dimorphism: new insights for drug intervention, Pharmacol. Ther. (2022), 108297.
- [6] Y. Carrasquillo, R.Wt Gereau, Activation of the extracellular signal-regulated kinase in the amygdala modulates pain perception, J. Neurosci.: Off. J. Soc. Neurosci. 27 (2007) 1543–1551.
- [7] Y. Carrasquillo, R.Wt Gereau, Hemispheric lateralization of a molecular signal for pain modulation in the amygdala, Mol. Pain. 4 (2008) 24.
- [8] S.R. Chen, H.L. Pan, Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats, J. Pharmacol. Exp. Ther. 312 (2005) 120–126.
- [9] L. Colloca, T. Ludman, D. Bouhassira, R. Baron, A.H. Dickenson, D. Yarnitsky, R. Freeman, A. Truini, N. Attal, N.B. Finnerup, C. Eccleston, E. Kalso, D.L. Bennett, R.H. Dworkin, S.N. Raja, Neuropathic pain, Nat. Rev. Dis. Prim. 3 (2017) 17002.
- [10] G. Corder, B. Ahanonu, B.F. Grewe, D. Wang, M.J. Schnitzer, G. Scherrer, An amygdalar neural ensemble that encodes the unpleasantness of pain, Science 363 (2019) 276–281.
- [11] C. Corti, L. Aldegheri, P. Somogyi, F. Ferraguti, Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS, Neuroscience 110 (2002) 403–420.
- [12] C. Goudet, E. Chapuy, A. Alloui, F. Acher, J.P. Pin, A. Eschalier, Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain, Pain 137 (2008) 112–124.
- [13] C. Goudet, B. Vilar, T. Courtiol, T. Deltheil, T. Bessiron, I. Brabet, N. Oueslati, D. Rigault, H.O. Bertrand, H. McLean, H. Daniel, M. Amalric, F. Acher, J.P. Pin, A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential, FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 26 (2012) 1682–1693.
- [14] K.J. Gregory, C. Goudet, International union of basic and clinical pharmacology. CXI. Pharmacology, signaling, and physiology of metabotropic glutamate receptors, Pharmacol. Rev. 73 (2021) 521–569.
- [15] K. Hargreaves, R. Dubner, F. Brown, C. Flores, J. Joris, A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia, Pain 32 (1988) 77–88.
- [16] P. Hasanein, M. Parviz, M. Keshavarz, K. Javanmardi, CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception, Clin. Exp. Pharmacol. Physiol. 34 (2007) 439–449.
- [17] J. Huang, V.M. Gadotti, L. Chen, I.A. Souza, S. Huang, D. Wang, C. Ramakrishnan, K. Deisseroth, Z. Zhang, G.W. Zamponi, A neuronal circuit for activating descending modulation of neuropathic pain, Nat. Neurosci. 22 (2019) 1659–1668.
- [18] K. Hull, J. Morstein, D. Trauner, In vivo photopharmacology, Chem. Rev. 118 (2018) 10710–10747.

- [19] G. Ji, V. Neugebauer, Hemispheric lateralization of pain processing by amygdala neurons, J. Neurophysiol. 102 (2009) 2253–2264.
- [20] B.J. Kolber, M.C. Montana, Y. Carrasquillo, J. Xu, S.F. Heinemann, L.J. Muglia, R. Wt Gereau, Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior, J. Neurosci.: Off. J. Soc. Neurosci. 30 (2010) 8203–8213.
- [21] M. Kremer, L.J. Becker, M. Barrot, I. Yalcin, How to study anxiety and depression in rodent models of chronic pain? Eur. J. Neurosci. 53 (2021) 236–270.
- [22] R. Kuner, T. Kuner, Cellular circuits in the brain and their modulation in acute and chronic pain, Physiol. Rev. 101 (2021) 213–258.
- [23] M. Mazzitelli, K. Marshall, A. Pham, G. Ji, V. Neugebauer, Optogenetic manipulations of amygdala neurons modulate spinal nociceptive processing and behavior under normal conditions and in an arthritis pain model, Front Pharmacol. 12 (2021), 668337.
- [24] M. Mazzitelli, P. Presto, N. Antenucci, S. Meltan, V. Neugebauer, Recent advances in the modulation of pain by the metabotropic glutamate receptors, Cells (2022) 11.
- [25] G. McKendrick, N.M. Graziane, Drug-induced conditioned place preference and its practical use in substance use disorder research, Front Behav. Neurosci. 14 (2020), 582147.
- [26] N. Mercer Lindsay, C. Chen, G. Gilam, S. Mackey, G. Scherrer, Brain circuits for pain and its treatment, Sci. Transl. Med. 13:eabj7 (2021) 360.
- [27] V. Neugebauer, Amygdala physiology in pain, Handb. Behav. Neurosci. 26 (2020) 101–113.
- [28] V. Neugebauer, M. Mazzitelli, B. Cragg, G. Ji, E. Navratilova, F. Porreca, Amygdala, neuropeptides, and chronic pain-related affective behaviors, Neuropharmacology 170 (2020), 108052.
- [29] E. Palazzo, Y. Fu, G. Ji, S. Maione, V. Neugebauer, Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors, Neuropharmacology 55 (2008) 537–545.
- [30] R.D. Palmiter, The parabrachial nucleus: CGRP neurons function as a general alarm, Trends Neurosci. 41 (2018) 280–293.
- [31] V. Pereira, C. Goudet, Emerging trends in pain modulation by metabotropic glutamate receptors, Front. Mol. Neurosci. 11 (2018) 464.
- [32] S. Pittolo, X. Gomez-Santacana, K. Eckelt, X. Rovira, J. Dalton, C. Goudet, J.P. Pin, A. Llobet, J. Giraldo, A. Llebaria, P. Gorostiza, An allosteric modulator to control endogenous G protein-coupled receptors with light, Nat. Chem. Biol. 10 (2014) 813–815.
- [33] P. Presto, M. Mazzitelli, R. Junell, Z. Griffin, V. Neugebauer, Sex differences in pain along the neuraxis, Neuropharmacology 210 (2022), 109030.
- [34] P. Presto, V. Neugebauer, Sex differences in CGRP regulation and function in the amygdala in a rat model of neuropathic pain, Front Mol. Neurosci. 15 (2022), 928587.
- [35] M. Roche, E. O'Connor, C. Diskin, D.P. Finn, The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats, Eur. J. Neurosci. 26 (2007) 2643–2653.
- [36] J.L. Sharp, T. Pearson, M.A. Smith, Sex differences in opioid receptor mediated effects: role of androgens, Neurosci. Biobehav. Rev. 134 (2022), 104522.
- [37] K.J. Sufka, Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain, Pain 58 (1994) 355–366.
- [38] O. van Hecke, S.K. Austin, R.A. Khan, B.H. Smith, N. Torrance, Neuropathic pain in the general population: a systematic review of epidemiological studies, Pain 155 (2014) 654–662.
- [39] B. Vilar, J. Busserolles, B. Ling, S. Laffray, L. Ulmann, F. Malhaire, E. Chapuy, Y. Aissouni, M. Etienne, E. Bourinet, F. Acher, J.P. Pin, A. Eschalier, C. Goudet, Alleviating pain hypersensitivity through activation of type 4 metabotropic glutamate receptor, J. Neurosci.: Off. J. Soc. Neurosci. 33 (2013) 18951–18965.
- [40] J. Wahis, A. Baudon, F. Althammer, D. Kerspern, S. Goyon, D. Hagiwara, A. Lefevre, L. Barteczko, B. Boury-Jamot, B. Bellanger, M. Abatis, M. Da Silva Gouveia, D. Benusiglio, M. Eliava, A. Rozov, I. Weinsanto, H.S. Knobloch-Bollmann, M.K. Kirchner, R.K. Roy, H. Wang, M. Pertin, P. Inquimbert, C. Pitzer, J. Siemens, Y. Goumon, B. Boutrel, C.M. Lamy, I. Decosterd, J.Y. Chatton, N. Rouach, W.S. Young, J.E. Stern, P. Poisbeau, R. Stoop, P. Darbon, V. Grinevich, A. Charlet, Astrocytes mediate the effect of oxytocin in the central amygdala on neuronal activity and affective states in rodents, Nat. Neurosci. 24 (2021) 529–541.
- [41] H. Wang, W. Jiang, R. Yang, Y. Li, Spinal metabotropic glutamate receptor 4 is involved in neuropathic pain, Neuroreport 22 (2011) 244–248.
- [42] I. Yalcin, Y. Bohren, E. Waltisperger, D. Sage-Ciocca, J.C. Yin, M.J. Freund-Mercier, M. Barrot, A time-dependent history of mood disorders in a murine model of neuropathic pain, Biol. Psychiatry 70 (2011) 946–953.
- [43] I. Yalcin, S. Megat, F. Barthas, E. Waltisperger, M. Kremer, E. Salvat, M. Barrot, The sciatic nerve cuffing model of neuropathic pain in mice, J. Vis. Exp. (2014).
- [44] P.D. Youell, R.G. Wise, D.E. Bentley, M.R. Dickinson, T.A. King, I. Tracey, A. K. Jones, Lateralisation of nociceptive processing in the human brain: a functional magnetic resonance imaging study, Neuroimage 23 (2004) 1068–1077.
- [45] C. Zussy, X. Gomez-Santacana, X. Rovira, D. De Bundel, S. Ferrazzo, D. Bosch, D. Asede, F. Malhaire, F. Acher, J. Giraldo, E. Valjent, I. Ehrlich, F. Ferraguti, J. P. Pin, A. Llebaria, C. Goudet, Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4, Mol. Psychiatry 23 (2018) 509–520.